Content Preview
Newsday 7 day/Optimum Online® subscribers click here for full access
Not a Newsday or Optimum Online® subscriber? Click here
Keryx treatment gets faster FDA review
Quick ReadKeryx Biopharmaceuticals cancer drug candidate gets faster regulatory review by FDA
NEW YORK (AP) — Keryx Biopharmaceuticals Inc. and AEterna Zentaris Inc. said Wednesday the Food and Drug Administration granted the potential cancer treatment Perifosine a fast-track review process.
The designation allows the agency to conduct a faster review of a drug candidate intended for a serious disease. Drug developers can submit their applications to the FDA piece by piece instead...
Newsday & ExploreLI are now available at no charge to Newsday 7-day and Optimum Online® subscribers. To continue reading, please log in or register now.
